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Summary Smoking is the major risk factor for the development of Chronic
Obstructive Pulmonary Disease (COPD), but epidemiological data suggest that other
etiological factors may also be involved. Chlamydia pneumoniae (Cpn) is an
established cause of acute and chronic upper and lower respiratory tract infections.
Data obtained from in vitro and in vivo studies indicate that Cpn infection can be
involved in the development of both small airways disease and emphysema, the two
major components of COPD. The aim of this study was to investigate the possible
association between chronic Cpn infection and COPD.
The study population was comprised of 199 consecutive patients who underwent
bronchoscopy due to longstanding airway symptoms and for whom spirometry and
serum samples for serology were available.
Acute and convalescent sera were analysed for specific IgG and IgA Cpn antibodies
using microimmunofluorescence. Chronic Cpn infection, defined as persistent
elevated titres of IgAX1/64, was present in 85 patients. Chronic infection was
associated with smoking and higher age, but no gender difference was observed.
Thirty patients had COPD, defined as FEV1/FVC o70% without any features of
asthma. Patients with COPD were older than those without, and there was no
association with gender in this group. A statistically significant association,
remaining after correction for smoking, was observed between chronic Cpn infection
and COPD, and there was a trend for decreasing lung function with increasing
antibody titres. The results suggest that chronic Cpn infection may be an
independent risk factor for the development of COPD.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is
one of the leading causes of morbidity and
mortality world-wide. It is well known that there
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with 10–20% of smokers developing COPD. However,
lifetime non smokers can also be at risk for
developing COPD,1 although the progression is not
usually as rapid as in smokers. The increased rate of
lung function deterioration seen in smoking COPD
patients often levels off to that of non-smokers
after smoking cessation,2 although some patients
have a continuous rapid decline despite smoking
cessation. These inconsistent findings regarding the
association between smoking and declining lung
function indicate that risk factors other than
smoking may be of importance for the development
of COPD. Chronic infections with adenovirus3 or
Chlamydia pneumoniae (Cpn) have been discussed
as possible additional risk factors associated with
the development of COPD. Cpn is an intracellular
bacterium associated with acute respiratory dis-
eases and has a tendency to cause chronic infec-
tions. This could trigger the development of COPD
by initiating release of cytokines and chemokines
and thereby sustaining an inflammatory response.
The aim of this study was to evaluate the
prevalence of chronic Cpn infection in patients
with longstanding airway symptoms, and to corre-
late serological findings with COPD, smoking habits
and gender. Consecutive patients referred for
bronchoscopy were investigated with lung function




In a prospective study performed February 1 1997–
February 28 1999, patients referred to the Depart-
ment of Respiratory Medicine, County Hospital of
G.avleborg, G.avle and underwent bronchoscopy
were evaluated regarding chronic Cpn infection.
The study base for this analysis consists of 403
consecutive patients without lung cancer, but with
long-standing airway symptoms and/or pathological
chest X-rays. Results from patients with lung cancer
have previously been described.4 All patients gave
an approval to participate after oral and written
information, and the Ethics Committee, Faculty of
Medicine, Uppsala University approved the study.
Spirometry was not available in 70 subjects, and
125 were excluded due to abnormal chest X-ray
findings that could influence the lung function (e.g.
sarcoidosis, status post tuberculosis, pulmonary
fibrosis, pneumonia, heart failure). This exclusion
was done without knowledge of the actual lung
function or antibody titres. Nine additional patients
were excluded either because serology specimens
were not collected before bronchoscopy (one), or
convalescent sera were missing (eight). 199 sub-
jects (110 females) remained for analysis. At the
bronchoscopy no intrabronchial findings that could
explain a reduction in lung function was observed in
any of the patients.
Blood specimens were collected for serology and
lung function tests were performed the day before
bronchoscopy. Convalescent serum was obtained
32–331 (median 97) days later (50–150 days after
the acute serum for 95% of the patients). During the
study period no Cpn epidemic occurred in the
county. Throat swabs as well as samples taken from
the bronchial mucosa with a cytobrush were
analysed for Cpn using polymerase chain reaction
(PCR) on samples taken during the first year. During
the second year immunohistochemistry was done
on formalin-fixed paraffin-embedded biopsies ob-
tained at bronchoscopy instead of PCR.
Pack-years of cigarette smoking were calculated
as the product of the duration of smoking (in years)
and the numbers of cigarettes smoked per day,
divided by 20.
In total, 30 patients were diagnosed with COPD
and 85 patients had chronic Cpn infection, as
defined below.
Serology for Cpn–Definition of chronic
infection
Blood specimens were analysed for specific anti-
bodies to Cpn by the microimmunofluorescence
(MIF) as described in detail earlier.5 Sera were
absorbed with Gullsorb (Gull Laboratories, USA) to
remove possible interference from IgG antibodies
before analysis of specific IgA antibodies. Repeat
blood specimens were always analysed in parallel
with earlier specimens on the same antigen slide to
increase the accuracy of titre level assignments for
all specimens from the same patients. Endpoint
titration was done in all cases, and control sera
were included in each run to ensure reproducibility.
Chronic Cpn infection was defined as stable titres
of specific IgAX1/64. Mean time between the
samples was 104 (SD 30) days. In total 85 subjects
(37% of the females and 49% of the males) had
serological signs of chronic infection.
PCR, throat specimens
Specimens were taken with a CTA swab (Chlamydia
trachomatis aluminum, Biohospital AB, Kopparberg,
Sweden) as described earlier.6 Swabs were im-
mersed in 2 SP medium, stored in the refrigerator,
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and transported to the laboratory the same day.
The specimens were either frozen at 701C or
immediately processed at the laboratory. Samples
were prepared for PCR using a previously described
method.7 PCR was done according to Campbell
et al.8 using HL1 and HR1 as primers on all samples.
All samples were run in duplicate for each PCR
method; one of the replicates was spiked with Cpn
DNA equivalent to 20 elementary bodies to test for
inhibitors of the Taq polymerase enzyme. When
inhibitors were found, specimen were diluted 1:100
with sterile deionized water and retested.
Immunohistochemistry (IHC)
IHC was done on small bronchial biopsies during the
second year of the study. Biopsies obtained at
bronchoscopy were formalin-fixed and embedded
in paraffin, then stained using a commercially
available kit employing streptavidin–biotin labelled
antibodies according to an earlier report.9 A
specific Cpn monoclonal antibody generously do-
nated by Dr Kenneth Persson, Malm .o, Sweden, was
used after the specificity of the antibody had been
ascertained. No cross-reactions were found in
control samples containing Chlamydia trachomatis
or Chlamydia psittaci. The monoclonal antibody
used was found to react in an identical manner to
RR-402, a specific Cpn monoclonal obtainable
commercially from DAKOPATTS, Denmark. This
monoclonal is specific for protein antigen moieties.
Phosphate-buffered saline, pH 7.4, fetal calf
serum, mouse serum and a monoclonal antibody
to CMV were used as negative controls. All analyses
were done by two microbiologists with extensive
experience with the methods.
Lung function testFDefinition of COPD
Spirometry was performed by trained nurses ac-
cording to the ATS criteria10 using a Vitalograph
Compact II (Vitalograph Ltd, Buckingham, Eng-
land), which was calibrated daily according to the
instructions from the manufacturer, and values
were calculated as percent of predicted values.11
COPD was defined as FEV1/FVCo70% without
features of asthma as judged from the medical
history or reversibility test (FEV1 reversibility
415%). Thirty-four patients had FEV1/FVCo70%,
two of them were reversible, and two had not
undergone reversibility testing or had not provided
a medical history excluding the possibility of
asthma. Thus, 30 patients were defined as having
COPD.
Statistical analysis
Comparisons of age, pack-years, lung function and
IgA titres for Cpn were performed by t-test, and
comparisons of sex, smoking status, and chronic
Cpn infection by the w2 test. The association
between COPD and chronic infection with Cpn was
calculated by analysis of covariance with COPD as
dependent factor, and current smoking status and
pack-years as covariates. The association between
lung function and convalescence serum titres of IgA
was calculated by analysis of covariance with FEV1/
FVC as a dependent factor, and current smoking
status and pack-years as covariates.
Results
No differences were found between males and
females regarding age, prevalence of chronic Cpn
infection, or current smoking status, but males had
a history of heavier smoking (pack-years), lower
FVC and FEV1/FVC, and higher antibody titres to
Cpn (Table 1).
Chronic infection was more common in ever
smokers; the pack-years smoked in those with
chronic infection was 19.3 (SD 17.7) and in those
without infection 13.7 (SD 16.4), Po0:05: The mean
age for those with chronic infection was 63.4 (SD
11.0) years and for those without 58.1 (SD 12.3)
years (Po0:01).
Patients with COPD were significantly older than
those without (Po0:01), but there was no signifi-
cant relationship between COPD diagnosis and
gender, Table 2.
COPD was more common among those with
chronic infection than in those without (22% vs
10%; Po0:05), a statistically significant difference
(Po0:05) even after correction for current smoking
status, pack-years smoked or age, and patients
with chronic infection had an increased incidence
of COPD in all pack-year categories (Fig. 1). The
degree of obstruction (FEV1% predicted) differed
between the treatment groups after correction for
smoking (Po0:05), and linear regression showed a
tendency to association with increasing titres of
specific Cpn IgA antibody titres, however this did
not reach statistical significance (Fig. 2).
PCR on throat specimens taken from 191 patients
was positive in 24 samples (13%). In cytobrush
specimens 6/78 (8%) were positive for Cpn DNA.
Three of the 6 brush positive PCR was also positive
in the throat sample. IHC on biopsies from the
bronchial mucous membrane was performed in 85
patients and 16 were found positive for Cpn. Two of
ARTICLE IN PRESS
22 E. Brand !en et al.
the IHC positive samples were positive with PCR on
throat specimen.
Comparing serological signs of chronic infection
with PCR on throat specimens we found that 12 of
85 (14%) with elevated IgA were positive (no throat
sample was collected from 3 of the patients). Of
the 114 without chronic Cpn infection 11 were
positive for Cpn DNA by PCR (10%).
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Table 2 Demography and serology for Chlamydia pneumoniae related to COPD.
COPDn (N¼ 30) Non-COPD (N¼ 169) P
Females % 40 58 n.s.
Age Median (range) 66 (48-84) 59 (22-84) o0.01
Current/Ex/Never smokers % 50/37/13 34/32/34 n.s.
Pack-years Mean (SD) 24.5 (17.4) 14.6 (17.4) o0.01
Serology for Cpn
IgA acute Geometric mean 88 39 o0.05
IgA convalescent Geometric mean 93 40 o0.05
Chronic Cpn infectionw % 63 39 o0.05
nFEV1/FVCo70% and no features of asthma.
wStable titres of IgAX1/64.
Table 1 Demography, lung function and serology for Cpn in the study population.
Females (N¼ 110) Males (N¼ 89) P
Age Median (range) 60 (22–84) 62 (35–84) n.s.
Current/Ex/Never smokers % 39/27/34 22/39/39 n.s.
Pack-years Mean (SD) 11.3 (13.9) 22.0 (18.9) o0.001
FEV1 (% predicted) Mean (SD) 87.3 (21.5) 81.8 (22.5) n.s.
FVC (% predicted) Mean (SD) 81.0 (18.5) 73.2 (19.2) o0.01
FEV1/FVC Mean (SD) 80.7 (9.3) 76.2 (11.2) o0.01
Serology for Cpn
IgA acute Geometric mean 29 72 o0.001
IgA convalescent Geometric mean 29 76 o0.001
Chronic Cpn infectionn % 37 49 n.s.
n.s.¼ not significant.
nStable titres of IgAX1/64.
Figure 1 Prevalence of COPD in relation to chronic Cpn
infection and smoking history.
Figure 2 FEV1 in relation to titres of IgA-antibodies to
Cpn in convalescent serum.
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Discussion
This study demonstrated an association between
chronic Cpn infection (stable titres of IgAX1/64)
and COPD (FEV1/FVCo70% and no features of
asthma). The association persisted after correction
for the potential confounding effect of smoking or
age. Lung function (FEV1% predicted) differed
significantly between titre classes, and showed a
tendency to decline with increasing titres.
Since patients were included consecutively,
and exclusion of patients with pathologic chest
X-ray was performed without knowledge about
their lung function or antibody titre, no selection
bias was introduced. However, since the recruit-
ment was based on a clinical requirement of
bronchoscopy, a generalisation to a general
COPD population should be done with caution;
results need to be confirmed in other cohorts of
COPD patients.
The presence of stable increased levels of serum
IgA, supporting a chronic infection, and Cpn-
specific circulating immune complexes have earlier
been described for COPD patients. von Hertzen
et al. reported that 65% of COPD patients (71% in
patients with severe disease) showed evidence of
suspected chronic Cpn infection.12 A recently
published study by Falck et al. confirmed an
association between Cpn IgA and decreased lung
function.13 On the other hand, Strachan et al
found no significant association between IgA anti-
bodies to Cpn and later treatment for chronic non-
specific lung disease or decline in lung function
in an epidemiological study focusing primarily on
cardiovascular risk factors.14 A trend was seen
for an increased rate of decline in lung function
in the IgA antibody positive patients, but con-
fidence intervals were wide since the study was
not powered for analysis of this variable. In
addition, these authors used a low cut-off level
for IgA (1/16) which may not select for chronic Cpn
infection.
We chose the microimmunofluorescence techni-
que for assessment of serostatus of these patients
because it is the ‘‘gold standard’’ for serology
recommended by the Centres for Disease Control
and Prevention (USA) and Laboratory Centre for
Disease Control (Canada) as long as the test is
performed in an experienced laboratory and is
interpreted by an experienced serologist.15
We attempted to confirm the presence of Cpn in
swab and biopsy samples using two different
methods, PCR and IHC. The correlation between
identification of Cpn positive patients by serology
and these methods demonstrating the presence of
DNA/antigen was poor, similarly as in lung cancer
patients.4 This is not surprising considering that the
sampling size of bronchial biopsies and throat
swabs is by necessity small. Cpn may have a patchy
distribution in the respiratory tract and it is
difficult to know where to take appropriate
samples.
Smoking has earlier been demonstrated to be
associated with increased levels of Cpn antibo-
dies.16,17 An association between raised specific
antibody titres to Cpn and COPD might be explained
by both being associated with smoking. However,
the association that we found between chronic Cpn
infection and COPD remained after correction for
actual smoking status and pack-years smoked, and
there was a trend towards decline in lung function
with increasing antibody titres. This could support
a causal relationship between chronic Cpn infection
and COPD.
Cpn is an ubiquitous pathogen; most individuals
experience two or three Cpn infections during a
lifetime.18 Males demonstrated higher IgA titres
than females, which is in accordance with a
previous study.19 The half-life of IgA antibodies is
short, 5–6 days,20 and persistent elevated levels of
specific IgA antibodies to Cpn have been suggested
as a marker for chronic Cpn infection,21,22 and
Gnarpe et al.19 showed that specific IgA titresX1/
64 do not normally occur in healthy blood donors.
For this reason, a stable titre of IgAX1/64 from at
least two serum specimens was chosen for the
serological definition of chronic Cpn infection used
in this study.
Cpn has been established as an etiologic agent
for acute upper and lower respiratory tract infec-
tions such as otitis, sinusitis, pharyngitis, bronchi-
tis, and pneumonia, and is involved in some (4–16%)
exacerbations of COPD.23,24 The organism can
cause asymptomatic infections in the respiratory
tract,25,26 but the long-term sequelae are un-
known. In vivo and in vitro studies have demon-
strated that Cpn is capable of infecting airway
epithelial,27 phagocytic,28 and endothelial and
smooth-muscle cells.29 Cpn has been shown to
cause ciliar dysfunction,30 which can contribute
to an increased susceptibility to pulmonary infec-
tion. Both humoral and cellular immunity are
involved in the immune response to chlamydia
infections, but intracellular chlamydiae are adept
at evading the immune defences, and the host does
not always seem to be capable of eradicating the
organism. Thus, prolonged, often sub-clinical in-
fections can occur. The host immune response can
be protective by limiting chlamydial reproduction,
but this may be a double-edged sword since the
same mechanisms may also contribute to the
establishment of a persistent infection which could
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result in damaging long-term consequences for
the host.
The pathological manifestations of COPD include
signs of ‘‘small airways disease’’ and/or emphyse-
ma to a varying degree. The pathogenetic mechan-
isms differ between these two components of
COPD, with cell proliferation in ‘‘small airways
disease’’, and degradation of connective tissue in
emphysema. Chronic infection with Cpn is hypothe-
sised to have the potential of contributing to both
of these manifestations.
‘‘Small airways disease’’ is characterised by
chronic obstructive bronchiolitis with infiltration
of neutrophils, lymphocytes and macrophages,
thickening of the airway wall, and increased muscle
mass. Two recent studies have demonstrated the
presence of Cpn in bronchioli, alveoli and alveolar
macrophages in COPD patients.31,32 Infection with
Cpn could lead to the stimulation of a continuous
inflammatory response resulting in an increased
production of IL-6 and basic fibroblast growth
factor (bFGF).33 This could contribute to sube-
pithelial fibrosis in small airways analogous to the
scarring observed in chronic Chlamydia trachomatis
infection of the eye (trachoma) or genital tract
(tubal infertility).34 Thus, Cpn theoretically has the
potential to cause tissue remodelling and the
‘‘small airways disease’’ seen in COPD.
Emphysema is defined by peribronchiolar de-
struction of alveolar attachments, airway collapse,
and enlargement of air spaces distal to the terminal
bronchioles. Imbalance between proteinases and
antiproteinases is suggested to be important in the
pathogenesis of emphysema.35 Cpn has been
identified in alveolar macrophages (AM) from
patients with emphysema,32 and these Cpn in-
fected phagocytes respond with a marked dose-
dependent release of reactive oxygen species, TNF-
a, IL-1b and IL-8, all of which may amplify a local
inflammatory response to Cpn without affecting
chlamydial infection and replication.36 Further,
infected macrophages in atherosclerotic plaques
have been demonstrated to produce elevated
levels of TNF-a and MMP-9,37 and since MMP-9 is
involved in connective tissue degradation, Cpn
infected AM may have a role in the development
of emphysema.
In conclusion, this study has demonstrated an
association between chronic Cpn infection and
COPD that persisted after correction for smok-
ing. This should be confirmed in other cohorts of
COPD patients. Treatment studies are also re-
quired to evaluate whether eradication of Cpn
improves symptoms of COPD and reduces the
accelerated decline in the lung function in these
patients.
Acknowledgements
This study was supported by grants from the Centre
for Research and Development Uppsala University-
G.avleborg, G.avle, and Karolinska Institutet, Stock-
holm, Sweden.
References
1. Stang P, Lydick E, Silberman C, Kempel A, Keating ET. The
prevalence of COPD: using smoking rates to estimate disease
frequency in the general population. Chest 2000;117(5
Suppl 2):354S–9S.
2. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of
smoking intervention and the use of an inhaled antic-
holinergic bronchodilator on the rate of decline of FEV1. The
Lung Health Study. JAMA 1994;272(19):1497–505.
3. Matsuse T, Hayashi S, Kuwano K, Keunecke H, Jefferies WA,
Hogg JC. Latent adenoviral infection in the pathogenesis of
chronic airways obstruction. Am Rev Respir Dis 1992;
146(1):177–84.
4. Koyi H, Brand !en E, Gnarpe J, Gnarpe H, Steen B. An
association between chronic infection with Chlamydia
pneumoniae and lung cancer. A prospective 2-year study.
APMIS 2001;109:572–80.
5. Falck G, Heyman L, Gnarpe J, Gnarpe H. Chlamydia
pneumoniae (TWAR): a common agent in acute bronchitis.
Scand J Infect Dis 1994;26(2):179–87.
6. Gnarpe J, Lundb.ack A, Gnarpe H, Sundel.of B. Comparison of
nasopharyngeal and throat swabs for the detection of
Chlamydia pneumoniae and Mycoplasma pneumoniae by
polymerase chain reaction. Scand J Infect Dis 1997;
104(Suppl.):11–2.
7. Gnarpe J, Eriksson K. Sample preparation for Chlamydia
pneumoniae PCR. APMIS 1995;103(4):307–8.
8. Campbell LA, Perez Melgosa M, Hamilton DJ, Kuo CC,
Grayston JT. Detection of Chlamydia pneumoniae by poly-
merase chain reaction. J Clin Microbiol 1992;30(2):434–9.
9. Naas J, Gnarpe JA. Demonstration of Chlamydia pneumoniae
in tissue by immunohistochemistry. APMIS 1999;107(9):
882–6.
10. ATS. Standards for the diagnosis and care of patients with
chronic obstructive pulmonary disease (COPD) and asthma.
This official statement of the American Thoracic Society was
adopted by the ATS Board of Directors, November 1986. Am
Rev Respir Dis 1987;136(1):225–244.
11. Berglund E, Birath G, Bjure J, et al. Spirometric studies in
normal subjects. Acta Med Scand 1963;173:185–92.
12. Von Hertzen L, Alakarppa H, Koskinen R, et al. Chlamydia
pneumoniae infection in patients with chronic obstructive
pulmonary disease. Epidemiol Infect 1997;118(2):155–64.
13. Falck G, Gnarpe J, Hansson LO, Svardsudd K, Gnarpe H.
Comparison of individuals with and without specific IgA
antibodies to Chlamydia pneumoniae: respiratory morbidity
and the metabolic syndrome. Chest 2002;122(5):1587–93.
14. Strachan DP, Carrington D, Mendall M, Butland BK, Yarnell
JW, Elwood P. Chlamydia pneumoniae serology, lung func-
tion decline, and treatment for respiratory disease. Am
J Respir Crit Care Med 2000;161(2 Pt 1):493–7.
15. Dowell SF, Peeling RW, Boman J, et al. Standardizing
Chlamydia pneumoniae assays: recommendations from the
centers for disease control and prevention (USA) and the
laboratory centre for disease control (Canada). Clin Infect
Dis 2001;33(4):492–503.
ARTICLE IN PRESS
Chronic Chlamydia pneumoniae and COPD 25
16. Hahn DL, Golubjatnikov R. Smoking is a potential confounder
of the Chlamydia pneumoniae-coronary artery disease
association. Arterioscler Thromb 1992;12(8):945–7.
17. Karvonen M, Tuomilehto J, Pitkaniemi J, Naukkarinen A,
Saikku P. Importance of smoking for Chlamydia pneumoniae
seropositivity. Int J Epidemiol 1994;23(6):1315–21.
18. Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory
tract pathogen: Chlamydia pneumoniae strain twar. J Infect
Dis 1990;161(4):618–25.
19. Gnarpe H, Gnarpe J, Lundback A. Evidence of 2 waves of
Chlamydia pneumoniae infection in Gavle, Sweden, 1990-
96. Scand J Infect Dis 1999;31(1):83–6.
20. Tomasi TB, Grey HM. Structure and function of immunoglo-
bulin A. Prog Allergy 1972;16:81–213.
21. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia
pneumoniae infection as a risk factor for coronary heart
disease in the Helsinki Heart Study. Ann Intern Med 1992;
116(4):273–8.
22. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin
L. Increased fibrinogen levels are associated with persistent
Chlamydia pneumoniae infection in unstable coronary artery
disease. Eur Heart J 1998;19(4):570–7.
23. Blasi F, Legnani D, Lombardo VM, et al. Chlamydia
pneumoniae infection in acute exacerbations of COPD. Eur
Respir J 1993;6(1):19–22.
24. Mogulkoc N, Karakurt S, Isalska B, et al. Acute purulent
exacerbation of chronic obstructive pulmonary disease and
Chlamydia pneumoniae infection. Am J Respir Crit Care Med
1999;160(1):349–53.
25. Gnarpe J, Gnarpe H, Sundelof B. Endemic prevalence of
Chlamydia pneumoniae in subjectively healthy persons.
Scand J Infect Dis 1991;23(3):387–8.
26. Gaydos CA, Roblin PM, Hammerschlag MR, et al. Diagnostic
utility of PCR-enzyme immunoassay, culture, and serology
for detection of Chlamydia pneumoniae in symptomatic and
asymptomatic patients. J Clin Microbiol 1994;32(4):903–5.
27. Wong KH, Skelton SK, Chan YK. Efficient culture of
Chlamydia pneumoniae with cell lines derived from the
human respiratory tract. J Clin Microbiol 1992;30(7):
1625–30.
28. Yang ZP, Cummings PK, Patton DL, Kuo CC. Ultrastructural
lung pathology of experimental Chlamydia pneumoniae
pneumonitis in mice. J Infect Dis 1994;170(2):464–7.
29. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn
TC. Replication of Chlamydia pneumoniae in vitro in human
macrophages, endothelial cells, and aortic artery smooth
muscle cells. Infect Immun 1996;64(5):1614–20.
30. Shemer-Avni Y, Lieberman D. Chlamydia pneumoniae-in-
duced ciliostasis in ciliated bronchial epithelial cells.
J Infect Dis 1995;171(5):1274–8.
31. Wu L, Skinner SJ, Lambie N, Vuletic JC, Blasi F, Black PN.
Immunohistochemical staining for Chlamydia pneumoniae is
increased in lung tissue from subjects with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
2000;162(3 Pt 1):1148–51.
32. Theegarten D, Mogilevski G, Anhenn O, Stamatis G,
Jaeschock R, Morgenroth K. The role of Chlamydia in the
pathogenesis of pulmonary emphysema. Electron micro-
scopy and immunofluorescence reveal corresponding find-
ings as in atherosclerosis. Virchows Arch 2000;437(2):190–3.
33. Rodel J, Woytas M, Groh A, et al. Production of basic
fibroblast growth factor and interleukin 6 by human smooth
muscle cells following infection with Chlamydia pneumo-
niae. Infect Immun 2000;68(6):3635–41.
34. Beatty WL, Byrne GI, Morrison RP. Repeated and persistent
infection with Chlamydia and the development of chronic
inflammation and disease. Trends Microbiol 1994;2(3):94–8.
35. Barnes PJ. Chronic obstructive pulmonary disease. N Engl
J Med 2000;343(4):269–80.
36. Redecke V, Dalhoff K, Bohnet S, Braun J, Maass M.
Interaction of Chlamydia pneumoniae and human alveolar
macrophages: infection and inflammatory response. Am
J Respir Cell Mol Biol 1998;19(5):721–7.
37. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat
shock protein 60 localizes in human atheroma and regulates
macrophage tumor necrosis factor-alpha and matrix metal-
loproteinase expression. Circulation 1998;98(4):300–7.
ARTICLE IN PRESS
26 E. Brand !en et al.
